The estimated Net Worth of Samuel Agresta is at least $1.45 Million dollars as of 16 August 2023. Samuel Agresta owns over 311,297 units of Infinity Pharmaceuticals stock worth over $6,226 and over the last 6 years he sold INFI stock worth over $0. In addition, he makes $1,440,340 as Director at Infinity Pharmaceuticals.
Samuel has made over 1 trades of the Infinity Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 311,297 units of INFI stock worth $1,158,025 on 16 August 2023.
The largest trade he's ever made was exercising 311,297 units of Infinity Pharmaceuticals stock on 16 August 2023 worth over $1,158,025. On average, Samuel trades about 28,300 units every 0 days since 2018. As of 16 August 2023 he still owns at least 311,297 units of Infinity Pharmaceuticals stock.
You can see the complete history of Samuel Agresta stock trades at the bottom of the page.
Dr. Samuel Agresta M.D. serves as Director of the Company. Dr. Agresta held several positions at Agios Pharmaceuticals, Inc., or Agios, a publicly traded biopharmaceuticals company, from 2011 to July 2018, most recently serving as Vice President and Head of Clinical Development since 2013. In this capacity he oversaw the development and approval of enasidineb and ivosidenib for the treatment of patients with acute myeloid leukemia that harbor isocitrate dehydrogenase mutations. Before joining Agios, Dr. Agresta held positions of responsibility in oncology clinical development at Merrimack Pharmaceuticals and Genentech, Inc., both publicly traded pharmaceuticals companies. Prior to his industry experience, Dr. Agresta served on the oncology faculty at the H. Lee Moffitt Cancer Center and Research Institute where he specialized in adolescent sarcoma care and participated in numerous industry trials. Dr. Agresta received his medical degree, internal medicine training, and served as chief resident at Tulane University School of Medicine in New Orleans. While in medical school, he also received a master’s degree in public health and tropical medicine from Tulane University School of Public Health. He completed his medical oncology fellowship at the University of South Florida and Moffitt Cancer Center and received a master’s degree in clinical investigation from the University of South Florida.
As the Director of Infinity Pharmaceuticals, the total compensation of Samuel Agresta at Infinity Pharmaceuticals is $1,440,340. There are 1 executives at Infinity Pharmaceuticals getting paid more, with Adelene Perkins having the highest compensation of $1,680,860.
Samuel Agresta is 47, he's been the Director of Infinity Pharmaceuticals since 2019. There are 14 older and 3 younger executives at Infinity Pharmaceuticals. The oldest executive at Infinity Pharmaceuticals Inc. is Anthony Evnin, 79, who is the Independent Director.
Samuel's mailing address filed with the SEC is 500 TECHNOLOGY SQUARE, STE 700, CAMBRIDGE, MA, 02139.
Over the last 18 years, insiders at Infinity Pharmaceuticals have traded over $485,846,497 worth of Infinity Pharmaceuticals stock and bought 22,639,120 units worth $175,155,554 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog..., and Medical Co L.P. Rosebay. On average, Infinity Pharmaceuticals executives and independent directors trade stock every 70 days with the average trade being worth of $14,976. The most recent stock trade was executed by Adelene Q Perkins on 8 September 2023, trading 768,133 units of INFI stock currently worth $15,363.
the mission of infinity pharmaceuticals, inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation. small molecule discovery and development capabilities infinity’s programs arise from the integration of a broad range of research and development capabilities, including strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation. strategic alliances building on its strengths in innovative small molecule drug discovery and development, infinity has established significant alliances with leading pharmaceutical and biotechnology companies to help realize the full potential of its product pipeline. business and scientific expertise the company has assembled a team of passionate, committed, and innovative individuals who bring together their collective expertise in all areas of business
Infinity Pharmaceuticals executives and other stock owners filed with the SEC include: